Burden of Clostridium difficile on the healthcare system
- PMID: 22752870
- PMCID: PMC3388018
- DOI: 10.1093/cid/cis335
Burden of Clostridium difficile on the healthcare system
Abstract
There are few high-quality studies of the costs of Clostridium difficile infection (CDI), and the majority of studies focus on the costs of CDI in acute-care facilities. Analysis of the best available data, from 2008, indicates that CDI may have resulted in $4.8 billion in excess costs in US acute-care facilities. Other areas of CDI-attributable excess costs that need to be investigated are costs of increased discharges to long-term care facilities, of CDI with onset in long-term care facilities, of recurrent CDI, and of additional adverse events caused by CDI.
Similar articles
-
Epidemiology of Clostridium difficile infection.J Pharm Pract. 2013 Oct;26(5):464-75. doi: 10.1177/0897190013499521. J Pharm Pract. 2013. PMID: 24064435 Free PMC article. Review.
-
Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.J Infect Chemother. 2018 Nov;24(11):892-901. doi: 10.1016/j.jiac.2018.07.020. Epub 2018 Sep 3. J Infect Chemother. 2018. PMID: 30190105
-
Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.Clin Infect Dis. 2018 Apr 17;66(9):1326-1332. doi: 10.1093/cid/cix1021. Clin Infect Dis. 2018. PMID: 29360950 Free PMC article.
-
Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study.Infection. 2020 Feb;48(1):129-132. doi: 10.1007/s15010-019-01368-5. Epub 2019 Nov 1. Infection. 2020. PMID: 31677084
-
Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.J Hosp Infect. 2014 Sep;88(1):12-21. doi: 10.1016/j.jhin.2014.04.011. Epub 2014 May 17. J Hosp Infect. 2014. PMID: 24996516 Review.
Cited by
-
A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection.Open Forum Infect Dis. 2024 Sep 30;11(10):ofae524. doi: 10.1093/ofid/ofae524. eCollection 2024 Oct. Open Forum Infect Dis. 2024. PMID: 39355263 Free PMC article.
-
New role for human α-defensin 5 in the fight against hypervirulent Clostridium difficile strains.Infect Immun. 2015 Mar;83(3):986-95. doi: 10.1128/IAI.02955-14. Epub 2014 Dec 29. Infect Immun. 2015. PMID: 25547793 Free PMC article.
-
A Clostridium difficile Cell Wall Glycopolymer Locus Influences Bacterial Shape, Polysaccharide Production and Virulence.PLoS Pathog. 2016 Oct 14;12(10):e1005946. doi: 10.1371/journal.ppat.1005946. eCollection 2016 Oct. PLoS Pathog. 2016. PMID: 27741317 Free PMC article.
-
Effectiveness of Bio-K+ for the prevention of Clostridioides difficile infection: Stepped-wedge cluster-randomized controlled trial.Infect Control Hosp Epidemiol. 2024 Apr;45(4):443-451. doi: 10.1017/ice.2023.169. Epub 2023 Dec 11. Infect Control Hosp Epidemiol. 2024. PMID: 38073551 Free PMC article. Clinical Trial.
-
Recurrent Clostridium difficile infection and the microbiome.J Gastroenterol. 2016 Jan;51(1):1-10. doi: 10.1007/s00535-015-1099-3. Epub 2015 Jul 8. J Gastroenterol. 2016. PMID: 26153514 Review.
References
-
- Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30:57–66. - PubMed
-
- Ghantoji SS, Sail K, Lairson DR, Dupont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309–18. - PubMed
-
- Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46:497–504. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical